Immunotherapy Clinical Trials

174 recruitingLast updated: July 10, 2026

There are 174 actively recruiting immunotherapy clinical trials across 28 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include Guangzhou, Guangdong, China, Shanghai, Shanghai Municipality, China, Shanghai, China. Updated daily from ClinicalTrials.gov.


Immunotherapy Trials at a Glance

174 actively recruiting trials for immunotherapy are listed on ClinicalTrialsFinder across 6 cities in 28 countries. The largest study group is Phase 2 with 72 trials, with the heaviest enrollment activity in Guangzhou, Shanghai, and Shanghai. Lead sponsors running immunotherapy studies include Sun Yat-sen University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, and Shanghai Juncell Therapeutics.

Browse immunotherapy trials by phase

Treatments under study

About Immunotherapy Clinical Trials

Looking for clinical trials for Immunotherapy? There are currently 118 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immunotherapy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immunotherapy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 174 trials

Recruiting
Not Applicable

Investigating Real-Time Immunotherapy Symptoms Study

CancerMelanoma (Skin Cancer)Immunotherapy
University of Pittsburgh40 enrolled1 locationNCT07280715
Recruiting
Phase 2

A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.

Biliary Tract Neoplasms Immunotherapy
Peking Union Medical College Hospital222 enrolled1 locationNCT07679399
Recruiting

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

Liver CancerColorectal, CancerEndometrial Cancer+12 more
Elephas2,000 enrolled8 locationsNCT07327489
Recruiting
Phase 2

Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer

Biliary Tract Neoplasms Immunotherapy
Peking Union Medical College Hospital70 enrolled1 locationNCT07670273
Recruiting
Phase 2

TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus

Immunotherapy-related Pruritus
University of California, San Diego28 enrolled1 locationNCT06748404
Recruiting

Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy

ImmunotherapyAdvanced Non-Small Cell Lung CancerNon-Small Cell Carcinoma of Lung
Cancer Institute and Hospital, Chinese Academy of Medical Sciences600 enrolled1 locationNCT07668037
Recruiting
Phase 2

A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial)

Rectal AdenocarcinomaImmunotherapyHigh-risk Locally Advanced+2 more
Sixth Affiliated Hospital, Sun Yat-sen University76 enrolled1 locationNCT07669220
Recruiting
Phase 2

Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab

Neoadjuvant ImmunotherapyMerkel Cell Carcinoma, Stage IMerkel Cell Carcinoma, Stage II
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest135 enrolled14 locationsNCT07387198
Recruiting
Phase 3

18F-FLUC PET/MR in Patients With Brain Mets

Brain MetastasisRadiation TherapyImmunotherapy, Active
University of Wisconsin, Madison30 enrolled1 locationNCT06159335
Recruiting
Phase 2

A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy

Consolidation ImmunotherapyChemoradiotherapyLimited-stage Small Cell Lung Cancer (LS-SCLC)+1 more
Shanghai Chest Hospital28 enrolled1 locationNCT07091305
Recruiting
Not Applicable

EXERCISE AND THE IMMUNE RESPONSE IN LUNG CANCER

Non-small Cell Lung CancerExercise TrainingImmunotherapy+1 more
Medical University of Graz50 enrolled1 locationNCT07267000
Recruiting

Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

Neoadjuvant TherapyNon-small Cell Lung CancerImmunotherapy+1 more
Peking University People's Hospital80 enrolled1 locationNCT07359040
Recruiting
Phase 1

Controlled Cold Exposure Combined With PD-1/PD-L1 Immunotherapy in Solid Tumors (NIVALIS)

Solid TumorsImmunotherapyCold Exposure+1 more
West China Hospital24 enrolled1 locationNCT07538479
Recruiting
Phase 2

Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer

Bladder CancerImmunotherapyLiquid Biopsy
Tianjin Medical University Second Hospital53 enrolled3 locationsNCT07475403
Recruiting
Phase 3

A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer

Rectal CancerRadiotherapyImmunotherapy+1 more
Tao Zhang444 enrolled1 locationNCT07113275
Recruiting

Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC

Nasopharyngeal CarcinomaMulti-omics TechniqueRecurrent and Metastatic Nasopharyngeal Carcinoma+1 more
Sun Yat-sen University50 enrolled1 locationNCT06197776
Recruiting
Not Applicable

Biofield Therapy for the Support of Immunotherapy-related Symptoms Among Adult Cancer Patients - A Pilot Study

PainCancerStress+2 more
University of California, Irvine12 enrolled2 locationsNCT07581080
Recruiting
Phase 1

Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors

Solid Tumor CancerSolid Tumor Cancer Treatment With Immunotherapy
Jun Zhou90 enrolled6 locationsNCT07584954
Recruiting

Imaging-based PRediction of Eligibility for ChemoImmunotherapy in reSEctable NSCLC, iPRECISE

NSCLCNeoadjuvant ChemoimmunotherapyCT
Samsung Medical Center150 enrolled1 locationNCT07559123
Recruiting
Phase 2

BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases

Hepatocellular CarcinomaRadiotherapyImmunotherapy+3 more
Shandong Cancer Hospital and Institute54 enrolled1 locationNCT07062055